AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia
Authors: Rots, MG Pieters, R Jansen, G Kaspers, GJL Van Zantwijk, CH Noordhuis, P Voorn, DA Van Wering, ER Creutzig, U Veerman, AJP Peters, GJ
Citation: Mg. Rots et al., A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia, EUR J CANC, 37(4), 2001, pp. 492-498
Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children
Authors: Mann, G Reinhardt, D Ritter, J Hermann, J Schmitt, K Gadner, H Creutzig, U
Citation: G. Mann et al., Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children, ANN HEMATOL, 80(7), 2001, pp. 417-422
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93
Authors: Creutzig, U Ritter, J Zimmermann, M Hermann, J Gadner, H Sawatzki, DB Niemeyer, CM Schwabe, D Selle, B Boos, J Kuhl, J Feldges, A
Citation: U. Creutzig et al., Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93, LEUKEMIA, 15(3), 2001, pp. 348-354
Reply to Wheatley and Hills: interpretation of subgroups in the AML-BFM 93study
Authors: Zimmermann, M Creutzig, U
Citation: M. Zimmermann et U. Creutzig, Reply to Wheatley and Hills: interpretation of subgroups in the AML-BFM 93study, LEUKEMIA, 15(11), 2001, pp. 1804-1804
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of study Acute Myeloid Leukemia - Berlin-Frankfurt-Munster 93
Authors: Creutzig, U Ritter, J Zimmermann, M Reinhardt, D Hermann, J Berthold, F Henze, G Jurgens, H Kabisch, H Havers, W Reiter, A Kluba, U Niggli, F Gadner, H
Citation: U. Creutzig et al., Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of study Acute Myeloid Leukemia - Berlin-Frankfurt-Munster 93, J CL ONCOL, 19(10), 2001, pp. 2705-2713
Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping
Authors: Wuchter, C Ratei, R Spahn, G Schoch, C Harbott, J Schnittger, S Haferlach, T Creutzig, U Sperling, C Karawajew, L Ludwig, WD
Citation: C. Wuchter et al., Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping, HAEMATOLOG, 86(2), 2001, pp. 154-161
Improved treatment results in children with AML: Results of study AML-BFM 93
Authors: Creutzig, U Berthold, F Boos, J Fleischhack, G Gadner, H Gnekow, A Graubner, U Henze, G Hermann, J Imbach, P Jurgens, H Kabisch, H Korholz, D Niemeyer, CM Reinhardt, D Reiter, A Ritter, J Spaar, HJ Zimmermann, M
Citation: U. Creutzig et al., Improved treatment results in children with AML: Results of study AML-BFM 93, KLIN PADIAT, 213(4), 2001, pp. 175-185
Preface
Authors: Creutzig, U Belohradsky, BH
Citation: U. Creutzig et Bh. Belohradsky, Preface, KLIN PADIAT, 213, 2001, pp. A3-A4
Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: a matter of controversies
Authors: Creutzig, U Reinhardt, D Zimmermann, M Klingebiel, T Gadner, M
Citation: U. Creutzig et al., Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: a matter of controversies, BLOOD, 97(11), 2001, pp. 3671-3672
In-vitro cellular drug resistance in acute non-lymhoblastic leukemia: Comparisons between adults and children
Authors: de Haas, TGKJ Zwaan, CM Wondergem, MJ Pieters, R Kaspers, GJL Loonen, AH Rottier, MMA Wunsche, R Creutzig, U Bartl, S Hahlen, K Broxterman, HJ Ossenkoppele, GJ Veerman, AJP
Citation: Tgkj. De Haas et al., In-vitro cellular drug resistance in acute non-lymhoblastic leukemia: Comparisons between adults and children, HEMAT BLOOD, 40, 2001, pp. 244-250
Risk-adapted therapy and randomization in children with AML: Preliminary results of study AML-BFM 93
Authors: Creutzig, U Ritter, J Zimmermann, M Hermann, J Gadner, H
Citation: U. Creutzig et al., Risk-adapted therapy and randomization in children with AML: Preliminary results of study AML-BFM 93, HEMAT BLOOD, 40, 2001, pp. 519-524
Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1
Authors: Wuchter, C Harbott, J Schoch, C Schnittger, S Borkhardt, A Karawajew, L Ratei, R Ruppert, V Haferlach, T Creutzig, U Dorken, B Ludwig, WD
Citation: C. Wuchter et al., Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1, LEUKEMIA, 14(7), 2000, pp. 1232-1238
3 x 14 mg/m(2) Idarubicin during induction: results of a pilot study in children with AML
Authors: Creutzig, U Korholz, D Niemeyer, CM Kabisch, K Graf, N Reiter, A Scheel-Walter, H Bender-Gotze, C Behnisch, W Hermann, J Mann, G Ritter, J Zimmermann, M
Citation: U. Creutzig et al., 3 x 14 mg/m(2) Idarubicin during induction: results of a pilot study in children with AML, LEUKEMIA, 14(2), 2000, pp. 340-342
Toxicity and effectivity of high-dose idarubicin during AML induction therapy: Results of a pilot study in children
Authors: Creutzig, U Korholz, D Niemeyer, CM Kabisch, H Graf, N Reiter, A Scheel-Walter, H Bender-Gotze, C Behnisch, W Hermann, J Mann, G Ritter, J Zimmermann, M
Citation: U. Creutzig et al., Toxicity and effectivity of high-dose idarubicin during AML induction therapy: Results of a pilot study in children, KLIN PADIAT, 212(4), 2000, pp. 163-168
Primary myelosarcomas are associated with a high rate of relapse: report on 34 children from the acute myeloid leukaemia-Berlin-Frankfurt-Munster studies
Authors: Reinhardt, D Pekrun, A Lakomek, M Zimmermann, M Ritter, J Creutzig, U
Citation: D. Reinhardt et al., Primary myelosarcomas are associated with a high rate of relapse: report on 34 children from the acute myeloid leukaemia-Berlin-Frankfurt-Munster studies, BR J HAEM, 110(4), 2000, pp. 863-866
Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity
Authors: Dubbers, A Wurthwein, G Muller, HJ Schulze-Westhoff, P Winkelhorst, M Kurzknabe, E Lanvers, C Pieters, R Kaspers, GJL Creutzig, U Ritter, J Boos, J
Citation: A. Dubbers et al., Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity, BR J HAEM, 109(2), 2000, pp. 427-429
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia
Authors: Zwaan, CM Kaspers, GJL Pieters, R Ramakers-Van Woerden, NL den Boer, ML Wunsche, R Rottier, MMA Hahlen, K van Wering, ER Janka-Schaub, GE Creutzig, U Veerman, AJP
Citation: Cm. Zwaan et al., Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia, BLOOD, 96(8), 2000, pp. 2779-2786
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia
Authors: Zwaan, CM Kaspers, GJL Pieters, R Woerden, NLR den Boer, ML Wunsche, R Rottier, MMA Hahlen, K van Wering, ER Janka-Schaub, GE Creutzig, U Veerman, AJP
Citation: Cm. Zwaan et al., Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia, BLOOD, 96(8), 2000, pp. 2879-2886
Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance
Authors: Schwartz, S Heinecke, A Zimmermann, M Creutzig, U Schoch, C Harbott, J Fonatsch, C Loffler, H Buchner, T Ludwig, WD Thiel, E
Citation: S. Schwartz et al., Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance, LEUK LYMPH, 34(1-2), 1999, pp. 85-94
Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7
Authors: Hasle, H Arico, M Basso, G Biondi, A Rajnoldi, AC Creutzig, U Fenu, S Fonatsch, C Haas, OA Harbott, J Kardos, G Kerndrup, G Mann, G Niemeyer, CM Ptoszkova, H Ritter, J Slater, R Stary, J Stollmann-Gibbels, B Testi, AM van Wering, ER Zimmermann, M
Citation: H. Hasle et al., Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7, LEUKEMIA, 13(3), 1999, pp. 376-385
The paediatric oncology and haematology net of competence
Authors: Creutzig, U Jurgens, H Henze, G
Citation: U. Creutzig et al., The paediatric oncology and haematology net of competence, KLIN PADIAT, 211(4), 1999, pp. 187-188
Computer-aided documentation and therapy planning in pediatric oncology - Introduction of a nationwide approach
Authors: Knaup, P Wiedemann, T Wolff, A Creutzig, U Haux, R Schilling, FH
Citation: P. Knaup et al., Computer-aided documentation and therapy planning in pediatric oncology - Introduction of a nationwide approach, KLIN PADIAT, 211(4), 1999, pp. 189-191
Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study
Authors: Kaspers, CJL Zwaan, CM Veerman, AJP Rots, MG Pieters, R Bucsky, P Domula, M Gobel, U Graf, N Havers, W Jorch, N Kabisch, K Spaar, HJ Ritter, J Creutzig, U
Citation: Cjl. Kaspers et al., Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study, KLIN PADIAT, 211(4), 1999, pp. 239-244
Primary isolated myelosarcoma in childhood
Authors: Reinhardt, D Pekrun, A Lakomek, M Ritter, J Creutzig, U
Citation: D. Reinhardt et al., Primary isolated myelosarcoma in childhood, KLIN PADIAT, 211(4), 1999, pp. 245-249
Prognosis, therapy realization and toxicity in nonresponders of study AML-BFM 87
Authors: Kallage, V Muller, JE Zimmermann, M Beck, JD Ritter, J Creutzig, U
Citation: V. Kallage et al., Prognosis, therapy realization and toxicity in nonresponders of study AML-BFM 87, KLIN PADIAT, 211(4), 1999, pp. 250-259
Risultati: 1-25 | 26-31